Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients

Abstract Background The 2020 National Comprehensive Cancer Network guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab‐paclitaxel (G‐nP) for borderline resectable/locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC). Aim The purpose of our study was to compare t...

Full description

Bibliographic Details

Published in:	Cancer Reports
Main Authors:	Myles A. Ingram, Brianna N. Lauren, Yoanna Pumpalova, Jiheum Park, Francesca Lim, Susan E. Bates, Fay Kastrinos, Gulam A. Manji, Chung Yin Kong, Chin Hur
Format:	Article
Language:	English
Published:	Wiley 2022-09-01
Subjects:	chemotherapy clinical cancer research pancreatic cancer
Online Access:	https://doi.org/10.1002/cnr2.1565